

Date: 1st March 2024

To,
 The Manager,
 National Stock Exchange of India Limited
 Listing Department
 Exchange Plaza
 5th Floor, Plot No. C/1, G Block,
 Bandra Kurla Complex
 Bandra (E), Mumbai – 400 051

NSE Symbol: SUVENPHAR

Ref: Application for obtaining approval under Regulation 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) for the scheme of amalgamation of Cohance Lifesciences Limited (“Transferor Company”) into and with Suven Pharmaceuticals Limited (“Transferee Company”) under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (“Scheme of Amalgamation”).

It is hereby certified that the draft scheme of amalgamation of Cohance Lifesciences Limited (“Transferor Company”) into and with Suven Pharmaceuticals Limited (“Transferee Company”) under Sections 230 to 232 of the Companies Act, 2013 and other applicable provisions (“Scheme of Amalgamation”) does not, in any way violate, override or limit the provisions of securities laws or requirements of the Stock Exchange(s) and the same is in compliance with the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and the master circular dated 20 June 2023 issued by the Securities and Exchange Board of India (“SEBI”), bearing reference no. SEBI/HO/CFD/POD-2/P/CIR/2023/93, as amended from time to time (“SEBI Master Circular”):

Sr. No.	Reference	Particulars	Compliance
1.	Regulations 17 to 27 of the SEBI Listing Regulations	Corporate governance requirements	Yes, complied.
2.	Regulation 11 of the SEBI Listing Regulations	Compliance with securities laws	Yes, complied.
Requirements of SEBI Circular			
(a)	Para (I)(A)(2)	Submission of documents to Stock Exchanges	Yes, complied.
(b)	Para (I)(A)(3)	Conditions for schemes of arrangement involving unlisted entities	Yes, complied. Noted for compliance with respect to the preparation of the abridged prospectus.
(c)	Para (I)(A)(4)(a)	Submission of Valuation Report	Yes, complied.
(d)	Para (I)(A)(5)	Auditors certificate regarding compliance with Accounting Standards	Yes, complied.

Suven Pharmaceuticals Limited

Regd. Office: 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue 7,
 Banjara Hills, Hyderabad - 500 034. Telangana, India. CIN : L24299TG2018PLC128171
 Tel: 91 40 2354 9414, Fax : 91 40 2354 1152, Email: info@suvенpharm.com, Website : suvenpharm.com

Sr. No.	Reference	Particulars	Compliance
(e)	Para (I)(A)(9)10	Provision of approval of public shareholders through e-voting	Noted for compliance.

For Suven Pharmaceuticals Limited



K. Hanumantha Rao
 Company Secretary & Compliance Officer
 Membership No. A11599

For Suven Pharmaceuticals Limited



V. Prasada Raju
 Managing Director
 DIN: 07267366

Certified that the transactions/ accounting treatment provided in the draft Scheme of Amalgamation involving the Transferor Company (i.e., Cohance Lifesciences Limited) and the Transferee Company (i.e., Suven Pharmaceuticals Limited) are in compliance with all the Accounting Standards applicable to a listed entity.

For Suven Pharmaceuticals Limited



Himanshu Agarwal
 Chief Financial Officer
 M.No. A92452



For Suven Pharmaceuticals Limited



V. Prasada Raju
 Managing Director
 DIN: 07267366

Suven Pharmaceuticals Limited